18 A phase 2 study to assess antiviral response, safety, and pharmacokinetics of albuferon™ in IFN-α NA1VE subjects with genotype 1 chronic hepatitis C

Journal of Hepatology ◽

10.1016/s0168-8278(05)81430-8 ◽

2005 ◽

Vol 42 ◽

pp. 9 ◽

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Antiviral Response ◽

Phase 2 ◽

Download Full-text

4 HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON™ (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT- NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C

Journal of Hepatology ◽

10.1016/s0168-8278(09)60006-4 ◽

2009 ◽

Vol 50 ◽

pp. S4 ◽

Author(s):

P. Kwo ◽

E. Lawitz ◽

J. McCone ◽

E. Schiff ◽

J. Vierling ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Phase 2 ◽

Phase 2 Study ◽

Treatment Naïve ◽

Peginterferon Alfa

Download Full-text

[11] PHASE 2 STUDY OF OMEGA INTERFERON ALONE OR IN COMBINATION WITH RIBAVIRIN IN SUBJECTS WITH CHRONIC HEPATITIS C GENOTYPE-1 INFECTION

Journal of Hepatology ◽

10.1016/s0168-8278(07)61609-2 ◽

2007 ◽

Vol 46 ◽

pp. S8 ◽

Author(s):

V. Novozhenov ◽

N. Zakharova ◽

E. Vinogradova ◽

I. Nikitin ◽

V. Gorbakov ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Phase 2 ◽

Download Full-text

Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials

Liver International ◽

10.1111/liv.12300 ◽

2013 ◽

Vol 34 (5) ◽

pp. 707-719 ◽

Author(s):

Michael P. Manns ◽

Jonathan McCone ◽

Mitchell N. Davis ◽

Lorenzo Rossaro ◽

Eugene Schiff ◽

...

Keyword(s):

Clinical Trials ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Safety Profile ◽

Phase 2 ◽

Combined Analysis ◽

Peginterferon Alfa

Download Full-text

[779] ANTIVIRAL RESPONSE AT WEEK 12 FOLLOWING COMPLETION OF TREATMENT WITH ALBINTERFERON a-2b PLUS RIBAVIRIN IN GENOTYPE 1, IFN-NAIVE, CHRONIC HEPATITIS C PATIENTS

Journal of Hepatology ◽

10.1016/s0168-8278(07)62377-0 ◽

2007 ◽

Vol 46 ◽

pp. S293 ◽

Author(s):

S. Zeuzem ◽

Y. Benhamou ◽

V. Bain ◽

D. Shouval ◽

S. Pianko ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Antiviral Response ◽

Chronic Hepatitis C Patients

Download Full-text

Virological response and safety outcomes in therapy–naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: A randomized, phase 2 study

Journal of Hepatology ◽

10.1016/j.jhep.2007.02.018 ◽

2007 ◽

Vol 47 (1) ◽

pp. 51-59 ◽

Author(s):

Robert G. Gish ◽

Sanjeev Arora ◽

K. Rajender Reddy ◽

David R. Nelson ◽

Christopher O’Brien ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Virological Response ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Phase 2 ◽

Phase 2 Study ◽

Pegylated Interferon Alfa ◽

Randomized Phase 2

Download Full-text

Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks for patients with chronic hepatitis C virus genotype 1 infection having shown slow antiviral response

10.1002/14651858.cd008516 ◽

2010 ◽

Author(s):

Lior H Katz ◽

Hadar Goldvaser ◽

Anat Gafter-Gvili ◽

Ran Tur-Kaspa

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Antiviral Response ◽

Virus Genotype ◽

Chronic Hepatitis C Virus

Download Full-text

Faculty Opinions recommendation of Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718367975.793494877 ◽

2014 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Clinical Trials ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Safety Profile ◽

Phase 2 ◽

Combined Analysis ◽

Peginterferon Alfa

Download Full-text

Open-label phase 2 study of faldaprevir, deleobuvir and ribavirin in Japanese treatment-naive patients with chronic hepatitis C virus genotype 1 infection

Hepatology Research ◽

10.1111/hepr.12535 ◽

2015 ◽

Vol 46 (3) ◽

pp. E189-E193

Author(s):

Hiroshi Yatsuhashi ◽

Nobuyoshi Kodani ◽

Hiroyuki Ugai ◽

Masao Omata

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Phase 2 ◽

Virus Genotype ◽

Phase 2 Study ◽

Chronic Hepatitis C Virus ◽

Open Label Phase ◽

Treatment Naïve

Download Full-text

1188 PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF NITAZOXANIDE WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN NONRESPONDERS (NR) WITH CHRONIC HEPATITIS C GENOTYPE 1: FINAL REPORT

Journal of Hepatology ◽

10.1016/s0168-8278(10)61189-0 ◽

2010 ◽

Vol 52 ◽

pp. S461 ◽

Author(s):

M.L. Shiffman ◽

A. Ahmed ◽

I.M. Jacobson ◽

R.E. Pruitt ◽

E.B. Keeffe

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Controlled Study ◽

Final Report ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Peginterferon Alfa

Download Full-text

817 POSITIVE PREDICTIVE VALUE OF EARLY ANTIVIRAL RESPONSE PROFILE WITH ALBINTERFERON ALFA-2B IN IFN-NAIVE PATIENTS WITH GENOTYPE 1, CHRONIC HEPATITIS C

Journal of Hepatology ◽

10.1016/s0168-8278(08)60819-3 ◽

2008 ◽

Vol 48 ◽

pp. S306

Author(s):

A.U. Neumann ◽

S. Zeuzem ◽

E. Yoshida ◽

Y. Benhamou ◽

S. Pianko ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Positive Predictive Value ◽

Chronic Hepatitis C ◽

Predictive Value ◽

Antiviral Response ◽

Response Profile

Download Full-text